AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2697484
Drug: Phenobarbitone (PB)
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (PB) therapy
Trial: 2697484
Drug: Sulphonylureas (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylureas (SU) plus metformin (M)
Trial: 341301
Drug: Ibuterol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuterol 0.75 mg
Trial: 341301
Drug: Terbutaline 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.50 mg
Trial: 16045526
Drug: Standard MEA
RxNorm normalized name: COCAMIDE MEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard MEA treatment after drug preparation
Trial: 12230594
Drug: MIG-99 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIG-99 6.25 mg t.i.d.
Trial: 12230594
Drug: MIG-99 (2.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIG-99 (2.08 mg; 6.25 mg; 18.75 mg t.i.d.)
Trial: 10025454
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia with intravenous conscious sedation and monitored anesthesia care
Trial: 7788826
Drug: 0.05 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg.kg‐1 morphine plus 3 micrograms.kg‐1 clonidine (M+C group; n = 10)
Trial: 7788826
Drug: 0.05 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg.kg‐1 morphine alone (M group; n = 10)
Trial: 2204698
Drug: rgp160 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rgp160 vaccine (40 or 80 micrograms)
Trial: 2204698
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Hepatitis B vaccine and placebo)
Trial: 913279
Drug: Aminophenazone two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophenazone two hours after oral intake in healthy children (control group)
Trial: 31571367
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser ablation combined with topical 5% 5-flurouracil application followed by NB‐UVB sessions for 4 months
Trial: 31012565
Drug: Red deer
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red deer mesenchymal stem cell extract (RCE) cream
Trial: 24145742
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (10 g over 3 to 5 days, or 8 g over 2 days)
Trial: 22111516
Drug: Blueberry (BB)
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry (BB) ingestion (250 g per day for 6 weeks and 375 g 1 hour prior to exercise)
Trial: 19927100
Drug: ProDisc-L (TDR)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProDisc-L (TDR) at L4/5
Trial: 19927100
Drug: ProDisc-L (TDR)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProDisc-L (TDR) at L5/S1
Trial: 16987338
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (group L)
Trial: 12722962
Drug: Fexofenadine 60
RxNorm normalized name: fexofenadine 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 60 mg and 120 mg
Trial: 10657410
Drug: Hypervolemic (HV)
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypervolemic (HV) therapy
Trial: 10657410
Drug: Normovolemic (NV)
RxNorm normalized name: NV-354
DrugBank: NV-354 (DB18392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normovolemic (NV) therapy
Trial: 10657410
Drug: Both HV
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HV and NV therapy
Trial: 9071714
Drug: Danaparoid sodium
RxNorm normalized name: Danaparoid Sodium
DrugBank: Danaparoid (DB06754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danaparoid sodium (750 anti-Xa units subcutaneously once-daily for 6 weeks)
Trial: 2428948
Drug: VAB-6 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAB-6 chemotherapy regimen (cyclophosphamide, vinblastine, bleomycin, dactinomycin, and cisplatin)
Trial: 2428948
Drug: VAB-6 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAB-6 chemotherapy regimen
Trial: 25885841
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% at 2 mg/kg body weight with 50 μg fentanyl
Trial: 25885841
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% at 2 mg/kg body weight with 100 μg fentanyl
Trial: 21962070
Drug: Intravenous iron(III)‐hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron(III)‐hydroxide sucrose (200 mg)
Trial: 9176645
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 0.8 mg b.i.d.
Trial: 8222166
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids (3 g/d)
Trial: 23575211
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 20,000 IU twice per week
Trial: 16036503
Drug: Pantoprazole (PAN)
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole (PAN) 8 mg/h + 80 mg bolus
Trial: 12585170
Drug: Zhongfeng No.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhongfeng No. II Oral Liquid (ZF II) plus western medicine
Trial: 12585170
Drug: Zhongfeng No.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhongfeng No. II Oral Liquid (ZF II) in animal model
Trial: 9312759
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (75 g) and i.v. glucagon test (1 mg)
Trial: 3827456
Drug: Deflazacort (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort (30 mg/d for four weeks)
Trial: 3827456
Drug: Prednisone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (25 mg/d for four weeks)
Trial: 30477836
Drug: Painting and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painting and handcrafting group art therapy (creative art therapy) for one month
Trial: 22456105
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Sexual intercourse twice a week for 3 months
Trial: 20107105
Drug: ROSI 4
RxNorm normalized name: EMROSI 40mg Extended-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSI 4 mg b.i.d.
Trial: 20107105
Drug: EXE 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXE 10 microg b.i.d. + ROSI 4 mg b.i.d.
Trial: 15800988
Drug: Device that
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device that applies kneading-like motion on the abdomen, used once daily for 20 min for 12 weeks
Trial: 12777952
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate, administered once a day orally for 12 months
Trial: 10392351
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) during induction
Trial: 10392351
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) at the end of CNS-directed therapy
Trial: 10392351
Drug: Neutrophil count
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutrophil count above 1 x 10(9)/l during continuation chemotherapy
Trial: 10392351
Drug: Neutrophil count
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutrophil count less than 1 x 10(9)/l during continuation chemotherapy
Trial: 8540453
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil group (4 g/day of fish oil concentrate)
Trial: 19564670
Drug: Intermittent negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent negative pressure wound therapy (NPWT) at lower pressures (‐75 mm Hg or ‐100 mm Hg)
Trial: 19564670
Drug: Continuous negative
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous negative pressure wound therapy (NPWT) at higher pressure (‐125 mm Hg)
Trial: 17520151
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of keratin peptide treatment
Trial: 17520151
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of keratin-active formulation
Trial: 14732296
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (final concentration 0.1, 1.0, and 10 mmol/L)
Trial: 11683967
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG therapy (21 patients)
Trial: 11683967
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C plus doxorubicin therapy (21 patients)
Trial: 11683967
Drug: Subsequent instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent instillation of the other intravesical therapy for non-responders
Trial: 11683967
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (BCG and mitomycin C plus doxorubicin)
Trial: 9843104
Drug: Thalidomide 400
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 400 mg daily for 5 days
Trial: 7857507
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract LI 160 (300 mg three times daily)
Trial: 356720
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3, 2 g/day)
Trial: 356720
Drug: Calcium p-chlorphenoxyisobutyrate
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docucal-P]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, 2 g/day)
Trial: 356720
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CaCO3 and Ca-CPIB
Trial: 356720
Drug: Calcium p-chlorphenoxyisobutyrate
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docucal-P]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium p-chlorphenoxyisobutyrate (Ca-CPIB, either singly or in combination)
Trial: 12779198
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous metoclopramide 8-hourly for 48 hours
Trial: 12779198
Drug: 5% saline
RxNorm normalized name: Breathe Free 0.65% Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% saline (control) 8-hourly for 48 hours
Trial: 9338902
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous metoclopramide
Trial: 10882145
Drug: Fluoxetine (FL)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FL) 40 mg single dose
Trial: 10882145
Drug: Fluoxetine (FL)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FL) 60 mg per day for 12 weeks
Trial: 10882145
Drug: Fluoxetine (FL)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FL) and Placebo (PL)
Trial: 3517250
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with LAK cells and IL-2
Trial: 23929659
Drug: Darexaban 60
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darexaban 60 mg
Trial: 27128609
Drug: Darexaban 60
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darexaban 60 mg with ketoconazole 400 mg once daily on Days 1-9
Trial: 19597409
Drug: Ketoprofen 10%
RxNorm normalized name: KETOPROFEN 10% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 10% spray gel (360 mg/die)
Trial: 19597409
Drug: Oral ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoprofen (25 mg t.i.d.)
Trial: 19597409
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pharmacological treatment)
Trial: 19597409
Drug: Ketoprofen 10%
RxNorm normalized name: KETOPROFEN 10% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 10% spray gel
Trial: 14601367
Drug: Epoetin alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alpha as an adjuvant treatment to preoperative autologous blood donation (PAD) program (40,000 IU weekly for 21, 14, and 7 days before surgery)
Trial: 14601367
Drug: Epoetin alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alpha alone (2 doses weekly for the same period)
Trial: 1332737
Drug: Metoclopramide 2
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 2 mg/kg every 2 h for five doses plus dexamethasone 10 mg and diphenhydramine
Trial: 4065703
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous morphine infusion
Trial: 1773325
Drug: Intermittent intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intramuscular morphine
Trial: 23749153
Drug: Half-molar sodium
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-molar sodium lactate (SL) infusion at 0.5 ml/kg/h for 48 hours
Trial: 23749153
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (control group)
Trial: 23749153
Drug: Half-molar sodium
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-molar sodium lactate (SL) infusion
Trial: 11445478
Drug: Flaxseed-supplemented, fat-restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed-supplemented, fat-restricted diet (30 g/day flaxseed, 20% of kilocalories or less from fat)
Trial: 8062886
Drug: Interleukin-3 (IL-3)
RxNorm normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-3 (IL-3) at doses of 0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d by subcutaneous injection for 21-day cycles
Trial: 8062886
Drug: Interleukin-3 (IL-3)
RxNorm normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-3 (IL-3) at doses of 5.0 micrograms/kg/d or higher
Trial: 3064773
Drug: Breast-preserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-preserving therapy
Trial: 3064773
Drug: Non-randomized group
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomized group (breast-preserving therapy)
Trial: 29146650
Drug: Iron syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron syrup (12.5 mg elemental iron)
Trial: 29146650
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient powders (MMPs including 12.5 mg elemental iron)
Trial: 26686508
Drug: DTP-HB-Hib vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP-HB-Hib vaccine (3 doses with 4-week intervals)
Trial: 15080855
Drug: SR 48692
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 48692 (90 mg)
Trial: 15080855
Drug: SR 48692
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 48692 (300 mg)
Trial: 15080855
Drug: SR 48692
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 48692 (90 mg) and (300 mg)
Trial: 9313662
Drug: 130 mg
RxNorm normalized name: pectin 130 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 mg free beta-sitosterol daily
Trial: 2444962
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of lysine
Trial: 27055427
Drug: Aerosolized N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized N-acetylcysteine (NAC), administered starting within 12 hours of mechanical ventilation, once every 8 hours until stopping mechanical ventilation.
Trial: 24361248
Drug: Amrubicin (40-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrubicin (40-45 mg/m² for ages 70-74; 40 mg/m² for ages ≥ 75) intravenously on days 1-3 every 3 weeks for 4-6 cycles
Trial: 24361248
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5 on day 1) and Etoposide (80 mg/m² on days 1-3) every 3 weeks for 4-6 cycles
Trial: 3756312
Drug: Bestatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin treatment (daily oral administration)
Trial: 28938325
Drug: Dexpanthenol-vitamin A
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol-vitamin A (Nazalnem) ointment applied to silastic splints
Trial: 27198947
Drug: GEn 600
RxNorm normalized name: collagen 6000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEn 600 mg
Trial: 27198947
Drug: GEn 1200
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEn 1200 mg
Trial: 25874578
Drug: GEn 600
RxNorm normalized name: collagen 6000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEn 600 mg and 1200 mg
Trial: 19772448
Drug: Standard Options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Options + AIR insulin
Trial: 17425817
Drug: Ondansetron 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.2 mg mL-1 with PCA morphine
Trial: 7492487
Drug: Cyclosporine G
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine G
Trial: 3732088
Drug: Potassium-conserving diuretic
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-conserving diuretic (amiloride)
Trial: 3732088
Drug: Potassium-losing diuretic
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-losing diuretic (chlorthalidone)
Trial: 31058784
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy control
Trial: 16674762
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac potassium sachets
Trial: 16674762
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac potassium tablets
Trial: 16674762
Drug: Both sachets
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sachets and tablets
Trial: 8791970
Drug: Cisapride, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 20 mg t.d.s.
Trial: 10155556
Drug: Short-term steroid
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term steroid therapy and PE with anti-viral therapy
Trial: 10155556
Drug: Anti-viral agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-viral agents and PE
Trial: 3898417
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine at night
Trial: 6099915
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cimetidine at night
Trial: 25499341
Drug: Intravenous fasudil
RxNorm normalized name: fasudil
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Intravenous fasudil (30 mg over 30 min)
Trial: 25499341
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost (5 μg)